Market Spotlight: Cervical Cancer
Market Spotlight: Cervical Cancer
$1,318.00
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Cervical Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 616,600 incident cases of cervical cancer worldwide, and expects that number to increase to 665,600 incident cases by 2029.
- Approved drugs for cervical cancer target cytotoxic T-lymphocyte antigen 4, vascular endothelial growth factor, topoisomerase I, programmed death-1 receptor (PD-1)/programmed death ligands (PD-L1 and PD-L2), the immune system, reactive oxygen species/free radicals, antibody-drug conjugate, and tissue factor. The majority of these therapies are administered via the intravenous route.
- The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with one drug in the NDA/BLA stage.
- Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, and intranasal formulations.
- High-impact upcoming events for drugs in the cervical cancer space comprise topline Phase I/II trial results for tiragolumab, topline Phase II trial results for bintrafusp alfa, an expected PDUFA date for biosimilar bevacizumab (Mylan/Biocon), and an estimated supplemental CHMP opinion for Libtayo.
- The overall likelihood of approval of a Phase I solid tumors asset is 12.3%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.8 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
- The US has a substantial lead in the number of cervical cancer clinical trials globally. Spain leads the major European markets, while China has the top spot in Asia.
- AstraZeneca and Roche have the highest number of completed clinical trials for cervical cancer, with 19 trials each. Merck & Co leads the industry sponsors with the highest overall number of clinical trials for cervical cancer, followed closely by AstraZeneca.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiotherapy
9 Chemotherapy
10 Targeted therapy
10 Immunotherapy
11 EPIDEMIOLOGY
14 MARKETED DRUGS
18 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Libtayo for Cervical Cancer (September 10, 2022)
26 GX-188E for Cervical Cancer (September 9, 2022)
28 Imfinzi for Cervical Cancer (March 24, 2022)
29 Libtayo for Cervical Cancer (January 28, 2022)
30 Balstilimab for Cervical Cancer (October 22, 2021)
31 Tivdak for Cervical Cancer (September 19, 2021)
33 Keytruda for Cervical Cancer (September 18, 2021)
35 Keytruda for Cervical Cancer (June 22, 2021)
37 Libtayo for Cervical Cancer (May 12, 2021)
38 Libtayo for Cervical Cancer (March 15, 2021)
41 KEY UPCOMING EVENTS
42 KEY REGULATORY EVENTS
42 Celltrion To Jostle For Space In Crowded EU Bevacizumab Market
42 China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut
42 Innovent And Etana Get Indonesian Bevacizumab Nod
43 CHMP Recommends Extension Of Indication For Keytruda
43 Libtayo’s Last-Minute Withdrawal
43 China’s NMPA Accepts Lee’s NDA For Socazolimab
43 Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal
44 Keytruda Cements Cervical Cancer Leadership With First-Line Nod
44 Seagen/Genmab’s Tivdak Set To Take On Merck’s Keytruda
45 PROBABILITY OF SUCCESS
46 LICENSING AND ASSET ACQUISITION DEALS
46 BriaCell Teams With Harvard To Advance Cancer Immunotherapies
46 GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
47 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
52 Recent events
55 BIBLIOGRAPHY
56 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of cervical cancer, 2020–29
18 Figure 2: Overview of pipeline drugs for cervical cancer in the US
18 Figure 3: Pipeline drugs for cervical cancer, by company
19 Figure 4: Pipeline drugs for cervical cancer, by drug type
19 Figure 5: Pipeline drugs for cervical cancer, by classification
26 Figure 6: Libtayo for Cervical Cancer (September 10, 2022): Phase III – EMPOWER
29 Figure 7: Imfinzi for Cervical Cancer (March 24, 2022): Phase III – CALLA
33 Figure 8: Tivdak for Cervical Cancer (September 19, 2021): Phase I/II – innovaTV 205
35 Figure 9: Keytruda for Cervical Cancer (September 18, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
37 Figure 10: Keytruda for Cervical Cancer (June 22, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
38 Figure 11: Libtayo for Cervical Cancer (May 12, 2021): Phase III – vs. Chemotherapy
40 Figure 12: Libtayo for Cervical Cancer (March 15, 2021): Phase III – vs. Chemotherapy
41 Figure 13: Key upcoming events in cervical cancer
45 Figure 14: Probability of success in the cervical cancer pipeline
49 Figure 15: Clinical trials in cervical cancer
49 Figure 16: Top 10 drugs for clinical trials in cervical cancer
50 Figure 17: Top 10 companies for clinical trials in cervical cancer
50 Figure 18: Trial locations in cervical cancer
51 Figure 19: Cervical cancer trials status
52 Figure 20: Cervical cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of cervical cancer, 2020–29
15 Table 2: Marketed drugs for cervical cancer
20 Table 3: Pipeline drugs for cervical cancer in the US
24 Table 4: Libtayo for Cervical Cancer (September 10, 2022)
26 Table 5: GX-188E for Cervical Cancer (September 9, 2022)
28 Table 6: Imfinzi for Cervical Cancer (March 24, 2022)
30 Table 7: Libtayo for Cervical Cancer (January 28, 2022)
31 Table 8: Balstilimab for Cervical Cancer (October 22, 2021)
32 Table 9: Tivdak for Cervical Cancer (September 19, 2021)
34 Table 10: Keytruda for Cervical Cancer (September 18, 2021)
36 Table 11: Keytruda for Cervical Cancer (June 22, 2021)
37 Table 12: Libtayo for Cervical Cancer (May 12, 2021)
39 Table 13: Libtayo for Cervical Cancer (March 15, 2021)
47 Table 14: Historical global sales, by drug ($m), 2017–21
48 Table 15: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Rheumatoid Arthritis 
Sign up to the